Ramelteon

BRAND NAMES

• Rozerem – the most widely recognized brand. 

• Circadin – available in some countries for insomnia treatment.

MECHANISM OF ACTION

Ramelteon is a selective melatonin receptor agonist that primarily binds to MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) of the hypothalamus, the brain’s central circadian clock. Activation of these receptors mimics the effects of natural melatonin, helping to regulate the sleep-wake cycle. Stimulation of MT1 receptors promotes sleep onset, while MT2 receptor activation helps phase-shift the circadian rhythm, supporting normal sleep timing. Unlike traditional hypnotics, ramelteon does not act on GABA receptors, so it has minimal risk of dependence, tolerance, or next-day sedation.

PHARMACOKINETICS

Absorption

Ramelteon is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 0.75 to 1.5 hours. Its oral bioavailability is low (about 1–2%) due to extensive first-pass metabolism in the liver. Food can slightly delay the time to peak concentration but does not significantly affect overall absorption.

Distribution

The mean volume of distribution for ramelteon is approximately(73.6{L}) following intravenous administration, indicating extensive distribution into tissues. It has high lipophilicity and high protein binding (~82%), which contributes to this substantial distribution away from the plasma.

Metabolism 

Ramelteon is extensively metabolized in the liver mainly by CYP1A2 to an active metabolite, M-II, which has weaker activity at melatonin receptors. Most of the drug in the bloodstream is present as metabolites.

Elimination

Ramelteon is mainly excreted in urine and a small amount in feces. The parent drug has a half-life of 1–2.5 hours, and its active metabolite lasts 2–5 hours.

PHARMACODYNAMICS

Ramelteon is a melatonin receptor agonist that selectively binds to MT1 and MT2 receptors in the suprachiasmatic nucleus of the hypothalamus, the brain’s circadian clock. Activation of MT1 receptors helps promote sleep onset, while MT2 receptor stimulation aids in regulating the sleep-wake cycle and adjusting circadian rhythms. Unlike traditional hypnotics, ramelteon does not act on GABA receptors, so it has minimal risk of dependence, tolerance, or next-day sedation. Its effects are primarily sleep-promoting rather than sedative, making it suitable for patients with difficulty falling asleep.

ADMINISTRATION

Ramelteon is administered orally in the form of tablets, usually taken 30 minutes before bedtime. It should be taken on an empty stomach for optimal absorption, as a high-fat meal can delay its onset of action. The usual dose is 8 mg once daily. It is intended for short-term or long-term treatment of insomnia characterized by difficulty falling asleepand should not be used to treat sudden awakenings during the night.

DOSAGE AND STRENGTH

• Adults: 8 mg orally once daily, taken 30 minutes before bedtime. 

• Elderly: Same as adults; no dosage adjustment required for age. 

• Formulation/Strength: 8 mg film-coated tablets.

DRUG INTERACTIONS

Ramelteon levels can increase with CYP1A2 inhibitors like fluvoxamine and decrease with CYP1A2 inducers like rifampin. CNS depressants may enhance drowsiness, and fluvoxamine is contraindicated.

FOOD INTERACTIONS

Ramelteon should be taken on an empty stomach for optimal effectiveness, as high-fat meals can delay absorption and reduce its sleep-promoting effects. Other than this, it has no significant food interactions.

CONTRAINDICATIONS

Ramelteon is contraindicated in patients with hypersensitivity, severe liver impairment, or those taking strong CYP1A2 inhibitors like fluvoxamine.

SIDE EFFECTS

• Dizziness 

• Fatigue 

• Somnolence (daytime sleepiness) 

• Nausea

OVER DOSE 

Ramelteon overdose can lead to excessive drowsiness, dizziness, fatigue, and nausea. Management involves supportive care, monitoring vital signs, and ensuring patient safety. Although generally not life-threatening, medical attention is recommended to prevent complications.

TOXICITY

Ramelteon has a low toxicity profile due to its selective action on melatonin receptors and lack of GABAergic activity. High doses may cause excessive sedation, dizziness, fatigue, or nausea, but serious toxic effects are rare. Management of toxicity is primarily supportive, focusing on monitoring vital signs and ensuring patient safety.